Verastem Oncology to Present at the Jefferies Virtual Healthcare Conference
May 28 2020 - 7:00AM
Business Wire
Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology),
a biopharmaceutical company committed to developing and
commercializing new medicines for patients battling cancer, today
announced that the Company will present at the Jefferies Virtual
Healthcare Conference on Thursday, June 4, 2020 at 2:30 p.m.
EDT.
A live webcast of the presentation will be available on the
investors section of the Company’s website at www.verastem.com. An
archived presentation will be available for 90 days.
About Verastem Oncology:
Verastem Oncology (Nasdaq: VSTM) is a commercial
biopharmaceutical company committed to the development and
commercialization of new medicines to improve the lives of patients
diagnosed with cancer. Our pipeline is focused on novel small
molecule drugs that inhibit critical signaling pathways in cancer
that promote cancer cell survival and tumor growth, including
phosphoinositide 3-kinase (PI3K), focal adhesion kinase (FAK) and
RAF/MEK inhibition.
Our first FDA approved product is available for the treatment of
patients with certain types of indolent non-Hodgkin’s lymphoma
(iNHL).
For more information, please visit www.verastem.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200528005057/en/
Verastem Oncology: Investors: John Doyle Vice President,
Investor Relations & Finance +1 781-469-1546
jdoyle@verastem.com Joseph Rayne Argot Partners +1 212 600 1902
joseph@argotpartners.com Media: Lisa Buffington Corporate
Communications +1 781-292-4205 lbuffington@verastem.com
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Apr 2023 to Apr 2024